Name | Number of supported studies | Average coverage | |
---|---|---|---|
non-classical monocyte | 7 studies | 37% ± 23% | |
microglial cell | 7 studies | 29% ± 12% | |
classical monocyte | 5 studies | 41% ± 19% | |
adipocyte | 5 studies | 24% ± 4% | |
enterocyte | 4 studies | 18% ± 3% | |
epithelial cell | 4 studies | 36% ± 15% | |
conventional dendritic cell | 3 studies | 49% ± 23% | |
macrophage | 3 studies | 27% ± 11% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 3 studies | 28% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 99% | 4669.93 | 224 / 226 | 97% | 91.08 | 393 / 406 |
breast | 87% | 3234.55 | 398 / 459 | 86% | 10.53 | 962 / 1118 |
prostate | 58% | 341.85 | 143 / 245 | 98% | 13.98 | 492 / 502 |
stomach | 60% | 383.87 | 215 / 359 | 92% | 32.20 | 263 / 286 |
lung | 63% | 687.18 | 364 / 578 | 87% | 16.17 | 1005 / 1155 |
intestine | 43% | 496.57 | 414 / 966 | 94% | 29.65 | 496 / 527 |
esophagus | 40% | 346.08 | 583 / 1445 | 90% | 22.80 | 164 / 183 |
bladder | 38% | 296.10 | 8 / 21 | 89% | 29.17 | 451 / 504 |
skin | 72% | 3522.94 | 1304 / 1809 | 43% | 4.40 | 203 / 472 |
brain | 21% | 116.75 | 552 / 2642 | 80% | 10.84 | 561 / 705 |
ureter | 0% | 0 | 0 / 0 | 100% | 13.03 | 1 / 1 |
thymus | 34% | 204.18 | 222 / 653 | 65% | 8.48 | 395 / 605 |
tonsil | 0% | 0 | 0 / 0 | 98% | 18.47 | 44 / 45 |
adipose | 96% | 4401.36 | 1157 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 17.12 | 27 / 29 |
pancreas | 18% | 82.48 | 58 / 328 | 72% | 9.27 | 129 / 178 |
uterus | 8% | 38.22 | 13 / 170 | 78% | 15.13 | 357 / 459 |
ovary | 1% | 2.43 | 1 / 180 | 76% | 9.78 | 328 / 430 |
peripheral blood | 65% | 938.82 | 603 / 929 | 0% | 0 | 0 / 0 |
kidney | 3% | 31.16 | 3 / 89 | 60% | 5.96 | 540 / 901 |
spleen | 43% | 232.94 | 104 / 241 | 0% | 0 | 0 / 0 |
muscle | 40% | 470.51 | 323 / 803 | 0% | 0 | 0 / 0 |
adrenal gland | 2% | 14.88 | 5 / 258 | 22% | 2.17 | 51 / 230 |
eye | 0% | 0 | 0 / 0 | 13% | 0.71 | 10 / 80 |
blood vessel | 10% | 124.08 | 128 / 1335 | 0% | 0 | 0 / 0 |
heart | 3% | 19.86 | 23 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0097009 | Biological process | energy homeostasis |
GO_0019221 | Biological process | cytokine-mediated signaling pathway |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0050873 | Biological process | brown fat cell differentiation |
GO_0006091 | Biological process | generation of precursor metabolites and energy |
GO_0030324 | Biological process | lung development |
GO_0071285 | Biological process | cellular response to lithium ion |
GO_1902034 | Biological process | negative regulation of hematopoietic stem cell proliferation |
GO_0045786 | Biological process | negative regulation of cell cycle |
GO_0007219 | Biological process | Notch signaling pathway |
GO_0001892 | Biological process | embryonic placenta development |
GO_0030225 | Biological process | macrophage differentiation |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0032436 | Biological process | positive regulation of proteasomal ubiquitin-dependent protein catabolic process |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_0008203 | Biological process | cholesterol metabolic process |
GO_0001889 | Biological process | liver development |
GO_0048839 | Biological process | inner ear development |
GO_0140467 | Biological process | integrated stress response signaling |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0045669 | Biological process | positive regulation of osteoblast differentiation |
GO_0071425 | Biological process | hematopoietic stem cell proliferation |
GO_0043032 | Biological process | positive regulation of macrophage activation |
GO_0002070 | Biological process | epithelial cell maturation |
GO_0071356 | Biological process | cellular response to tumor necrosis factor |
GO_0006351 | Biological process | DNA-templated transcription |
GO_0030851 | Biological process | granulocyte differentiation |
GO_0070102 | Biological process | interleukin-6-mediated signaling pathway |
GO_0007005 | Biological process | mitochondrion organization |
GO_0000050 | Biological process | urea cycle |
GO_0030099 | Biological process | myeloid cell differentiation |
GO_0045600 | Biological process | positive regulation of fat cell differentiation |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0055088 | Biological process | lipid homeostasis |
GO_0050729 | Biological process | positive regulation of inflammatory response |
GO_0071407 | Biological process | cellular response to organic cyclic compound |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0050872 | Biological process | white fat cell differentiation |
GO_0051726 | Biological process | regulation of cell cycle |
GO_0042593 | Biological process | glucose homeostasis |
GO_0045444 | Biological process | fat cell differentiation |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005730 | Cellular component | nucleolus |
GO_0005654 | Cellular component | nucleoplasm |
GO_0090575 | Cellular component | RNA polymerase II transcription regulator complex |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_1990647 | Cellular component | C/EBP complex |
GO_0036488 | Cellular component | CHOP-C/EBP complex |
GO_0000785 | Cellular component | chromatin |
GO_0005667 | Cellular component | transcription regulator complex |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0000976 | Molecular function | transcription cis-regulatory region binding |
GO_0019900 | Molecular function | kinase binding |
GO_0097677 | Molecular function | STAT family protein binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0061629 | Molecular function | RNA polymerase II-specific DNA-binding transcription factor binding |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0031490 | Molecular function | chromatin DNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | CEBPA |
Protein name | CCAAT/enhancer-binding protein alpha (C/EBP alpha) |
Synonyms | CEBP |
Description | FUNCTION: Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes . During early embryogenesis, plays essential and redundant functions with CEBPB. Essential for the transition from common myeloid progenitors (CMP) to granulocyte/monocyte progenitors (GMP). Critical for the proper development of the liver and the lung (By similarity). Necessary for terminal adipocyte differentiation, is required for postnatal maintenance of systemic energy homeostasis and lipid storage (By similarity). To regulate these different processes at the proper moment and tissue, interplays with other transcription factors and modulators. Down-regulates the expression of genes that maintain cells in an undifferentiated and proliferative state through E2F1 repression, which is critical for its ability to induce adipocyte and granulocyte terminal differentiation. Reciprocally E2F1 blocks adipocyte differentiation by binding to specific promoters and repressing CEBPA binding to its target gene promoters. Proliferation arrest also depends on a functional binding to SWI/SNF complex . In liver, regulates gluconeogenesis and lipogenesis through different mechanisms. To regulate gluconeogenesis, functionally cooperates with FOXO1 binding to IRE-controlled promoters and regulating the expression of target genes such as PCK1 or G6PC1. To modulate lipogenesis, interacts and transcriptionally synergizes with SREBF1 in promoter activation of specific lipogenic target genes such as ACAS2. In adipose tissue, seems to act as FOXO1 coactivator accessing to ADIPOQ promoter through FOXO1 binding sites (By similarity). .; FUNCTION: [Isoform 3]: Can act as dominant-negative. Binds DNA and have transctivation activity, even if much less efficiently than isoform 2. Does not inhibit cell proliferation . .; FUNCTION: [Isoform 4]: Directly and specifically enhances ribosomal DNA transcription interacting with RNA polymerase I-specific cofactors and inducing histone acetylation. . |
Accessions | ENST00000498907.3 [P49715-1] P49715 |